Free Biopharma Stock Content

$XBI $94.36 | -2.98% Covid Updates $NVAX -4.1% Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of...

BULL THESIS VKTX overall corporate summary Focus on novel therapeutics for metabolic and endocrine diseases, especially NASH As of...

$XBI $97.26 | +4.65% Covid Updates $IGMS +9.4% IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment...

(Updated 3/24/22 based on quarterly report) BULL THESIS INO Corporate and summary ~ $400M in cash (~2 years) Extensive clinical pipeline...

$XBI $92.94 | -0.33% Covid Updates $NVAX -12.0% Novavax falls short of COVID-19 vaccine deliveries - Reuters. source $IMNM -4.3%...

$XBI $93.25 | +2.8% Covid Updates $RDHL -5.5% RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and...

BULL THESIS PDSB overall corporate and summary Immuno-oncology company with novel cancer vaccine technology Initial efficacy results...

As February begins, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD...

$XBI $90.79 | +1.5% Covid Updates $NVAX +1.0% - New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine. source...

$XBI $89.44 | -2.62% Covid Updates $NVAX -1.1% Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing...

$XBI $91.85 | -3.3% Covid Updates $AVIR -3.7% Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527)...

Below we review moves from smid-cap biopharma companies during January 2022. See Table 1 for monthly moves for companies and categories...

$XBI $94.94 | +1.62% Covid Updates $PFE +0.7% & $BNTX +4.4% Pfizer and BioNTech Initiate Rolling Submission for Emergency Use...

$XBI $93.43 | +5.48% Covid Updates $MRNA +6.2% Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax source $NVAX +13.0%...

As the last full week of January comes to a close, we review moves from smid-cap biopharma companies during this past week. See Table 1...

$XBI $88.58 | +3.59% Covid Updates $SRNE +2.8% Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly...

$XBI $85.51 | -4.55% Covid Updates $TFFP -8.5% TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation...

(Updated on 3/24/22 based on quarterly report) BULL THESIS FGEN overall corporate and executive summary FGEN has lots of cash and revenue...

(Updated 3/24/22 based on quarterly report) BULL THESIS ITCI overall corporate and executive summary ITCI currently has no debt ITCI has...

(Updated on 8/31/22 based on quarterly report) BULL THESIS SUMMARY CARA overall corporate and summary IV Korsuva Recently approved...